Company

Tenax Therapeutics, Inc.

Tenax Therapeutics develops treatments for pulmonary hypertension and other cardiopulmonary diseases.

About

Founded in 1967 and based in Chapel Hill, US, Tenax Therapeutics develops therapies for severe cardiopulmonary conditions, including pulmonary hypertension. Its candidates include TNX-201 and TNX-103. In August 2024, it secured USD 100 mn through a PIPE deal led by BVF Partners to support development of phase 3 treatments.

1Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in